

Resource Summary Report

Generated by [kravitz2](#) on Jul 30, 2026

OncoKB

RRID:SCR_014782

Type: Tool

Proper Citation

OncoKB (RRID:SCR_014782)

Resource Information

URL: <http://oncokb.org>

Proper Citation: OncoKB (RRID:SCR_014782)

Description: Precision oncology knowledge base which contains information about the effects and treatment implications of specific cancer gene alterations. OncoKB contains detailed information about specific alterations in 418 cancer genes. Each variant entry contains biological effect, prevalence, prognostic information, and treatment implications. Information is curated from various sources, such as guidelines from the FDA, ClinicalTrials.gov, and scientific literature by a network of clinical fellows, research fellows, and faculty members at Memorial Sloan Kettering Cancer Center.

Resource Type: data or information resource, database, portal

Keywords: oncology, knowledge base, cancer, cancer gene, gene alteration, curation, somatic mutation, FASEB list

Related Condition: Cancer

Availability: Public

Resource Name: OncoKB

Resource ID: SCR_014782

License URLs: <http://oncokb.org/#!/terms>

Record Creation Time: 20220129T080322+0000

Record Last Update: 20260729T044355+0000

Ratings and Alerts

No rating or validation information has been found for OncoKB.

No alerts have been found for OncoKB.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 826 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Browne IM, et al. (2026) The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(1), 148.

Botticelli A, et al. (2026) The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(1), 45.

Lloyd MR, et al. (2026) Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(1), 169.

Chang LJ, et al. (2026) Assessment of Circulating Tumor DNA for Early Detection of Hepatocellular Carcinoma in Alpha-Fetoprotein-Negative Patients With Cirrhotic Nodules. JGH open : an open access journal of gastroenterology and hepatology, 10(1), e70331.

Luo M, et al. (2025) Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations. Cancer discovery, 15(3), 511.

Ku AT, et al. (2025) Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF- β Activity Driving Tumor Recurrence. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(24), 5211.

Yadav S, et al. (2025) Genomic and Immune Landscape of Pancreatic Ductal Adenocarcinoma Associated with Germline Pathogenic Variants in ATM. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(21), 4463.

Keane S, et al. (2025) Comprehensive characterization and targeted treatment of a pediatric epithelioid glioblastoma with a rare TRIM24-NTRK2 fusion. NPJ precision oncology, 9(1), 394.

Kim KH, et al. (2025) Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial. Cancer research and treatment, 57(4), 968.

Jaidee R, et al. (2025) Establishment and genomic profiling of cholangiocarcinoma cells with functional characterization. *Scientific reports*, 15(1), 8621.

McCoon P, et al. (2025) Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(10), 1931.

Verkerk K, et al. (2025) The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP). *ESMO open*, 10(1), 104112.

Rekhtman N, et al. (2025) Chromothripsis-Mediated Small Cell Lung Carcinoma. *Cancer discovery*, 15(1), 83.

Martín-Arana J, et al. (2025) Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer. *Nature cancer*, 6(6), 1000.

Beaudry FEG, et al. (2025) Molecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System. *Current oncology (Toronto, Ont.)*, 32(2).

Qu X, et al. (2025) Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer. *Nature communications*, 16(1), 4332.

Gregoricchio S, et al. (2025) Endometrial tumorigenesis involves epigenetic plasticity demarcating non-coding somatic mutations and 3D-genome alterations. *Genome biology*, 26(1), 124.

Kinnersley B, et al. (2025) Genomic landscape of diffuse glioma revealed by whole genome sequencing. *Nature communications*, 16(1), 4233.

Pavlířková K, et al. (2025) Correlation between p53 immunoexpression and TP53 mutation status in extrapulmonary small cell neuroendocrine carcinomas and its association with patient survival. *Virchows Archiv : an international journal of pathology*, 487(3), 557.

Sanabria-Salas MC, et al. (2025) Clinical integration of germline findings from a tumor testing precision medicine program. *BMC cancer*, 25(1), 176.